Thus, the contemporary targeting of senescence by senotherapeutic drugs along with target therapy toward ERBB family members may boost the efficacy of future cancer treatment (Zhu et al., 2015; Schafer et al., 2017; Ovadya and Krizhanovsky, 2018; Romaniello et al., 2022). This evidence concerns the gene EGFR and cancer.